{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"mobilize lymphocytes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"lymphocytes infused post transplant"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"not able to mobilize stem cells/no transplant"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.","groups":[{"description":"azacitidine: 75 mg/sq m daily for 5 days\n\nlenalidomide: 10 mg p.o. daily, Days 6-21","id":"OG000","title":"5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant"}],"paramType":"NUMBER","populationDescription":"17 of 17 patients were able to mobilize lymphocytes. 16 of 17 patients had lymphocytes infused post transplant. 1 patient was not able to mobilize stem cells and so did not go to transplant.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment","type":"PRIMARY","unitOfMeasure":"participants"}